Genmab
GMAB
211 hedge funds and large institutions have $1.58B invested in Genmab in 2021 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 67 increasing their positions, 84 reducing their positions, and 28 closing their positions.
11% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 28
1% more call options, than puts
Call options by funds: $292K | Put options by funds: $288K
0% more funds holding
Funds holding: 211 → 211 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.58% less ownership
Funds ownership: 65.11% → 60.53% (-4.6%)
17% less capital invested
Capital invested by funds: $1.89B → $1.58B (-$314M)
20% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 84
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$7.32M |
| 2 |
State Street
Boston,
Massachusetts
|
+$6.24M |
| 3 |
Millennium Management
New York
|
+$5.79M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$4.28M |
| 5 |
Optiver Holding
Amsterdam,
Netherlands
|
+$2.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$60.3M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$32.8M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$21.9M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$19.1M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$11.1M |
GMAB Hedge Fund Activity: Q4 2021 in Review
211 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q4 2021, worth a combined $1.58B — down 17% from $1.89B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new GMAB positions and 28 closed out — a net gain of 3 holders — while 67 added to existing stakes and 84 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $7.32M. The largest seller was BlackRock, cutting an estimated $60.3M.
- 211 institutional investors held Genmab (GMAB) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $1.58B of Genmab stock for Q4 2021, down 17% quarter-over-quarter.
- 31 funds opened new Genmab positions in Q4 2021 and 28 closed out, a net change of +3 holders.
- The largest Genmab buyer in Q4 2021 was Renaissance Technologies, an estimated $7.32M added.
- The largest Genmab seller in Q4 2021 was BlackRock, an estimated $60.3M sold.
Based on aggregated 13F filings for Q4 2021.